This is part of CRN’s Associate Member Spotlight series and reflects the views, opinions, and expertise of the featured member company, SGS Nutrasource. The content is provided for informational purposes only and does not represent the views, positions, or policies of the Council for Responsible Nutrition.
Even strong safety data can fail if the FDA submission isn’t built correctly.
To help companies better navigate this complex regulatory process, a new article from SGS Nutrasource breaks down the NDIN pathway, why many notifications receive FDA objection letters, and how the NDIN process compares to the GRAS framework.
Yes, and: This article highlights the most common regulatory pitfalls, particularly gaps in manufacturing detail, ingredient characterization, and safety evidence, any of which can derail an otherwise solid dossier. It also outlines how a more strategic, well-prepared approach can significantly improve the chances of a successful submission and a smoother path to market.
Go deeper: View the full article here.